Omnigen DFU Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03483467|
Recruitment Status : Recruiting
First Posted : March 30, 2018
Last Update Posted : August 13, 2018
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Foot Ulcers||Other: Omnigen Other: Dummy Packaging||Not Applicable|
This pilot study is designed as a multi-centre prospective, patient and observer blind, randomised controlled trial, recruiting patients from two clinical centres across the East Midlands; Derby Teaching Hospitals NHS Foundation Trust (DHFT) and Nottingham University Hospitals NHS Trust (NUH).
Eligible patients will be approached within diabetic foot clinics by their usual clinical carers to determine whether they are interested in participating in the study. They will be provided with written information about the study and the researcher will explain the study verbally to them and address any questions and concerns the patient may have. Patents will be given at least 24 hours to consider taking part in the trial before signing a consent form.
After informed consent has been given, baseline information will be collected. This will include demographic information, medical history and concomitant medication. eGFR and HbA1c will also be collected if not done within previous 3 months as part of standard care. The baseline wound status, assessment of ulcer infection according to Infectious Diseases Society of America (IDSA) criteria, peripheral pulses, neuropathy and ankle brachial pressure index will also be taken.
Participants will then be randomised to receive either standard of care or Omnigen graft with standard of care. Staff administering the Omnigen product will be aware of which treatment the participant is receiving however the participant and the research staff conducting the healing assessments will be blinded to their treatment allocation. Therefore the participant and the assessors will be blinded to the treatment given in order to minimize any bias in the collection of healing outcome data. For those randomized into the control arm, 'Dummy Packaging' will be used to ensure the blind is maintained.
Patients will be seen two weekly from their baseline visit until healing for up to 12 weeks and at 2 weeks post healing in those that heal. If a participant's foot ulcer heals before the final 12 weeks visit, they will attend a healing confirmation visit two weeks post the original heal date, however will not be required to attend any further fortnightly visits until the final blinded assessment visit at week 12 . If the participant's foot ulcer has not healed at 12 weeks then a blinded assessment should still be conducted at this time point.
Data is collected using the Dacima Clinical Suite Electronic Data Capture (EDC) software (Dacima Software Inc.)
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Pilot Study - Effectiveness of Omnigen in Addition to Standard Treatment in Treating Diabetic Foot Ulcers (DFU)|
|Actual Study Start Date :||March 11, 2018|
|Estimated Primary Completion Date :||September 1, 2019|
|Estimated Study Completion Date :||April 1, 2020|
Application of Omnigen
For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
Placebo Comparator: 2
Dummy Omnigen Packaging
Other: Dummy Packaging
For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
- The primary outcome is wound healing (defined as full epithelialisation without drainage maintained for 2 weeks) within 12 weeks of starting study treatment. [ Time Frame: 12 weeks ]To assess the whether higher proportion of wounds heal at 12 weeks in the investigational arm to the control arm - assessed by confirmation of healing at 12 week visit.
- Overall reduction in wound size (surface area, assessed by acetate tracing) [ Time Frame: 12 weeks ]To assess the whether higher proportion of wounds reduce in size at 12 weeks in the investigational arm to the control arm - assessed by comparing acetate tracing in each arm.
- Time to healing (weeks) for those that heal within 12 weeks, [ Time Frame: 12 weeks ]To assess the whether higher proportion of wounds heal at 12 weeks in the investigational arm to the control arm - assessed by proportion of confirmation of heeling visits conducted at 12 weeks within each arm.
- Proportion of wounds healed within 6 weeks [ Time Frame: 6 weeks ]To assess the whether higher proportion of wounds heal at 6 weeks in the investigational arm to the control arm - assessed by proportion of confirmation of heeling visits conducted at 6 weeks within each arm.
- Adverse events (safety) including major and minor amputations and hospitalisation [ Time Frame: 12 weeks ]To assess the safety of the intervention of Omnigen in comparison to standard of care. Review of SAEARs.
- Incidence of secondary infection [ Time Frame: 12 weeks ]To assess the safety of the intervention of Omnigen in comparison to standard of care. Review of SAEARs.
- Feasibility of recruitment [ Time Frame: 12 weeks ]To assess the feasibility of the study in regards to recruitment for a future full RCT. Recruitment rate, reasons for patients not randomising and reasons for investigators not randomising. Screening logs/protocol deviations.
- Pain in the area of the ulcer as assessed by patient completed VAS [ Time Frame: 12 weeks ]To assess pain of ulcer through completion of VAS at every fortnightly visit to identify if pain reduces at a higher rate on the interventional arm than the control arm.
- Effectiveness of participant blind [ Time Frame: 12 weeks ]To assess whether the blinding to arm allocation has been successful with the use of dummy packaging or whether the participants are able to identify which treatment they have received. This will be done by completion of a participant questionnaire at the end of the study.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03483467
|Contact: Kate Frost||01332 firstname.lastname@example.org|
|Contact: Frances Game||01332 email@example.com|
|University Hospitals Derby and Burton, Royal Derby Hospital||Recruiting|
|Derby, United Kingdom|
|Contact: Fran Prof Game|
|University of Nottingham Teachig Hospitals, City Hospital||Recruiting|
|Nottingham, United Kingdom|
|Contact: Dr Chokklingham|